Watanobe H, Tamura T
Third Department of Internal Medicine, Hirosaki University School of Medicine, Aomori, Japan.
Neuropeptides. 1995 Feb;28(2):115-24. doi: 10.1016/0143-4179(95)90083-7.
GH-secreting pituitary adenomas causing acromegaly can be classified into at least two types, i.e. the lactotroph-like adenoma and somatotroph-like adenoma. From a functional point of view, the lactotroph-like adenoma is characterized by positive GH responses to TRH and bromocriptine (Br) with a GH increase or decrease, respectively, whereas the somatotroph-like adenoma is characterized by a high GH response to GHRH and a low GH response to TRH and Br. In this study, we examined whether the loading of vasoactive intestinal peptide (VIP) and GnRH, another hypothalamic hormone capable of stimulating GH secretion in acromegaly, have a pathophysiological significance as TRH, GHRH, and Br tests. In 52 patients with active acromegaly, we performed iv bolus injections of TRH (500 micrograms), GHRH (100 micrograms), VIP (100 micrograms), and GnRH (100 micrograms), and a peroral administration of Br (2.5 mg), in order to compare the GH responses to these loads. There was a significant correlation that the higher was the GH response after TRH the greater was the GH decrease after Br. Although statistically insignificant, there was a trend (0.05 < p < 0.1) that the higher was the GH response after GHRH the smaller was the GH decrease after Br. In addition, as novel findings, we observed that the GH responses to GHRH, VIP, and GnRH were in significant positive correlations to each other, and that the higher were the GH responses after VIP and GnRH the smaller was the GH decrease after Br. In agreement with this, we also found that a simultaneous GH responsivity to VIP and/or GnRH in TRH-responsive acromegalics significantly enhanced the GH response to GHRH and lowered the Br responsiveness compared to the data of pure TRH-responders. From these results, we hypothesize that the positive GH responsiveness to VIP and GnRH, like that to GHRH, may be a feature of the somatotroph-like pituitary adenoma causing acromegaly. The present results appear to be of some help in understanding the basis of the great variabilities in the GH responses to various dynamic testings in acromegaly.
导致肢端肥大症的生长激素分泌型垂体腺瘤至少可分为两种类型,即催乳素细胞样腺瘤和生长激素细胞样腺瘤。从功能角度来看,催乳素细胞样腺瘤的特征是对促甲状腺激素释放激素(TRH)和溴隐亭(Br)的生长激素反应呈阳性,分别表现为生长激素升高或降低,而生长激素细胞样腺瘤的特征是对生长激素释放激素(GHRH)的生长激素反应高,对TRH和Br的生长激素反应低。在本研究中,我们研究了血管活性肠肽(VIP)和促性腺激素释放激素(GnRH,另一种能够刺激肢端肥大症患者生长激素分泌的下丘脑激素)负荷是否具有与TRH、GHRH和Br试验相同的病理生理学意义。在52例活动性肢端肥大症患者中,我们静脉推注TRH(500微克)、GHRH(100微克)、VIP(100微克)和GnRH(100微克),并口服Br(2.5毫克),以比较生长激素对这些负荷的反应。TRH后生长激素反应越高,Br后生长激素降低越大,二者之间存在显著相关性。虽然在统计学上无显著意义,但存在一种趋势(0.05<p<0.1),即GHRH后生长激素反应越高,Br后生长激素降低越小。此外,作为新发现,我们观察到生长激素对GHRH、VIP和GnRH的反应之间存在显著正相关,VIP和GnRH后生长激素反应越高,Br后生长激素降低越小。与此一致,我们还发现,与单纯TRH反应者的数据相比,TRH反应性肢端肥大症患者对VIP和/或GnRH的同时生长激素反应性显著增强了对GHRH的生长激素反应,并降低了对Br的反应性。基于这些结果,我们推测,生长激素对VIP和GnRH的阳性反应性,与对GHRH的反应性一样,可能是导致肢端肥大症的生长激素细胞样垂体腺瘤的一个特征。目前的结果似乎有助于理解肢端肥大症患者对各种动态试验的生长激素反应存在巨大差异的原因。